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Abstract
Background: Cervical cancer, caused by specific oncogenic types of human papillomavirus (HPV), is the second most 
common cancer in women worldwide. A large number of young sexually active women get infected by HPV but only a 
small fraction of them have persistent infection and develop cervical cancer pointing to co- factors including host 
genetics that might play a role in outcome of the HPV infection. This study investigated the role of CCR2-V64I 
polymorphism in cervical cancer, pre-cancers and HPV infection in South African women resident in Western Cape. 
CCR2-V64I polymorphism has been previously reported to influence the progression to cervical cancer in some 
populations and has also been associated with decreased progression from HIV infection to AIDS.
Methods: Genotyping for CCR2-V64I was done by PCR-SSP in a case-control study of 446 women (106 black African 
and 340 mixed-ancestry) with histologically confirmed invasive cervical cancer and 1432 controls (322 black African 
and 1110 mixed-ancestry) group-matched (1:3) by age, ethnicity and domicile status. In the control women HPV was 
detected using the Digene Hybrid Capture II test and cervical disease was detected by cervical cytology.
Results: The CCR2-64I variant was significantly associated with cervical cancer when cases were compared to the 
control group (P = 0.001). Further analysis comparing selected groups within the controls showed that individuals with 
abnormal cytology and high grade squamous intraepitleial neoplasia (HSIL) did not have this association when 
compared to women with normal cytology. HPV infection also showed no association with CCR2-64I variant. 
Comparing SIL positive controls with the cases showed a significant association of CCR2-64I variant (P = 0.001) with 
cervical cancer.
Conclusions: This is the first study of the role of CCR2-V64I polymorphism in cervical cancer in an African population. 
Our results show that CCR2-64I variant is associated with the risk of cervical cancer but does not affect the susceptibility 
to HPV infection or HSIL in South African women of black and mixed-ancestry origin. This result implies that the role of 
CCR2 is important in invasive cancer of the cervix but not in HPV infection or in the development of pre-cancers.
Background
Cervical cancer is the second leading cause of cancer and
cancer related mortality in women worldwide with
493,243 cases and 273,505 deaths per year [1]. The inci-
dence and mortality rates have dropped significantly in
developed countries due to effective cervical screening
programs thus 83% of all new cervical cancer cases and
85% of all cervical cancer-related deaths now occur in
developing countries where screening programs are poor
[2]. Cervical cancer is the most common cancer and the
highest cause of cancer death in women in sub-Saharan
Africa accounting for 22% of all cancers in women [3].
Squamous cell carcinoma of the cervix arises from the
pre-cancer lesions of squamous intraepithelial lesions
(SIL) [4] which are further divided into low-grade (LSIL)
and high-grade (HSIL) stages. LSILs are pre-cancerous
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and considered as the very early precursor stages of cervi-
cal cancer with very few cases progressing to cancer [5]
while most HSILs progress to invasive cervical cancer
(ICC) when left untreated [6]. Cervical cancer is a multi-
step process that develops slowly over several years after
persistent infection of epithelial cells with oncogenic
types of human papillomavirus (HPV), mainly types 16
and 18. Many women become infected with HPV during
their life-time but most are able to clear the infection.
Less than 1% of the clinically detectable HPV infections
progress to cervical cancer [7]. This indicates that addi-
tional risk factors play an important role in the develop-
ment of the cancer of the cervix. These risk factors
include host and viral genetic factors as well as environ-
mental and life style factors [8]. The possibility of genetic
predisposition is strengthened by the observation of a
double risk of developing cervical cancer in biological
first degree relatives [9] with these factors most likely
influencing response to HPV infection and its persis-
tence. The involvement of macrophages, natural killer
(NK) cells and T-cells in papilloma regression further
point to the role of genes associated cell-mediated immu-
nity (CMI) in the risk of infection and persistence of HPV
[8]. Data showing increased incidence of SIL in
immusuppressed women and in immunocompromised
patients as well as in immunomanipulated animal models
show a strong role of the immune system in controlling
the infection [7,10].
One of the earliest responses of human body to injury
or infection is the release of chemokines that triggers
recruitment of local inflammatory and immune cells.
Chemokines are chemoattractant cytokines that regulate
migration of leukocytes by binding to G-protein coupled
cell-surface receptors. It has been postulated that HPV
disrupts the interaction between epithelial cells and the
i m m u n e  s y s t e m  b y  d e r e g u l a t i n g  t h e  e x p r e s s i o n  o f
chemokines which can be mediated by (HPV) E7 which
interacts with IRF-1 [11].
Chemokine receptor 2 or CCR2, has affinity for CCL2
(monocyte chemoattractant protein-1 (MCP-1)), CCL7,
CCL8 and CCL13 ligands and is expressed on basophils,
monocytes, dendritic cells (DCs), activated T-cells and
NK cells. CCR2 is a major receptor for the MCP-1 which
is produced largely by tumour cells [12,13] and is respon-
sible for recruiting macrophages to tumours in bladder,
cervix, ovary, lung and breast. The role of macrophages in
tumour development and control is multifactorial. In
early stages, macrophages have tumour cytotoxic charac-
teristics but once tumour cells have evaded the immune
system they switch to play a role in tumour angiogenesis
[14-16]. A pilot study done by Riethdorf et al. (1996)
showed that 1/6 high grade squamous intraepithelial neo-
plasia expressed MCP-1 compared to 4/5 squamous cell
cervical caracinomas [17] suggesting that MCP-1 plays a
greater role in invasive cancers compared to pre-cancers.
This was further confirmed by in situ hybridisation stud-
ies [18] where MCP-1 expression was detected in the
stoma surrounding the tumour particularly at the inva-
sion front.
CCR2 gene is localized on chromosome 3p21 within a
cluster of chemokine receptor genes. It has two isoforms;
CCR2A and CCR2B products of the CCR2 gene as a
result of alternative splicing. A single nucleotide poly-
morphism (SNP) of G to A at position 190 of CCR2 gene
changes amino acid valine (GTC) to isoleucine (ATC) at
codon 64 (CCR2-V64I). This conservative amino acid
change takes place in the first transmembrane domain of
CCR2A and CCR2B [19]. This change makes CCR2A
more stable and increases its half-life but does not in any
way affect the stability of CCR2B isoform [19]. The
CCR2-V64I polymorphism has been extensively studied
and several reports show an association of the CCR2-64I
variant with reduced risk of progression to AIDS in HIV-
infected individuals, [20-23], multiple sclerosis [24] and
development of breast cancer [25]. It is also associated
with increased risk of carotid atherosclerosis [26] and
reduction in the risk of renal transplant rejection [27].
There are conflicting reports on the role of the CCR2-
V64I polymorphism in the development or risk to cervi-
cal cancer [28-31]. A study comparing SIL patients to ICC
p a t i e n t s  i n  a  P o r t u g u e s e  p o p u l a t i o n  r e p o r t e d  t h a t  t h e
CCR2-64I  variant was associated with reduced risk of
developing ICC from HSIL [29]. The same group con-
ducted a case-control study in the same population com-
paring women with HSIL to a control group and found
CCR2-64I variant as a risk allele for developing HSIL [28].
Among two studies in Swedish population the first study
[30] reported that the CCR2-64I variant was associated
with decreased risk of developing cervical cancer. The
second Swedish study did not find any association of
CCR2-64I variant with either HPV infection or cancer of
the cervix [31].
Epidemiological studies have demonstrated the impor-
tance of host genetic susceptibility factors in the develop-
ment of cervical cancer. A twin study [32] and a mother-
daughter family study [33] demonstrated a hereditary
component of cervical tumours. Biological first-degree
relatives of women with cancer of the cervix showed an
increased risk of developing cervical cancer compared to
non-biological relatives of women with cervical cancer
[9]. There are conflicting reports on the role of the CCR2-
V64I polymorphism in cervical cancer and furthermore,
none of these studies have been done in African popula-
tion, thus, we therefore investigated the role of CCR2-
V64I  p o l y m o r p h i s m  i n  r i s k  o f  c a n c e r  o f  t h e  c e r v i x  i n
South African women of black and mixed-ancestry ori-
gin.Chatterjee et al. BMC Cancer 2010, 10:278
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Methods
Participants
A total of 1878 subjects comprising 446 women with
invasive cervical cancer (106 black African and 340
women of mixed-ancestry) and 1432 controls (322 black
African and 1110 women of mixed-ancestry) without
cancer of the cervix were recruited in a cross-sectional
study. Incident cases of symptomatic invasive cervical
epithelial cancer (stage 1b-IVb), diagnosed a maximum of
six months previously were recruited from Groote
Schuur Hospital and Tygerberg Hospital in the Western
Cape Province, South Africa. Hospital controls were
series matched in a ratio of 3:1 to the cases on decade of
age, ethnic group and area of residence (urban/rural).
Most of the Black African subjects originally came from
either the Transkei, in the Eastern Cape of South Africa
while their Mixed Ancestry group refers to a group of
people that show highest level of intercontinental admix-
ture of any global population resulting from gene flow
between Black Africans, Western Europeans, Khoisans,
Indians, East Asians (eg. Malaysians) and Cushitics who
settled in the Western Cape region [34]. There were 264
(59%) urban cases and 182 (41%) rural cases compared to
718 (53%) urban controls and 632 (47%) rural controls
(residency status was not known for 82 controls). The
cases and controls formed part of a study to investigate
the association of oral contraceptives with cervical cancer
[35,36].
The mean age for black cases was 43.8 yrs (SD 9.2) and
for mixed-ancestry cases it was 46.0 yrs (SD 8.1). The
mean age for black controls was 42.3 yrs (SD 9.0) and for
mixed-ancestry controls it was 44.3 yrs (SD 8.4). The HIV
infection status was 4.8% for the cases and 4.7% for the
controls. No significant differences in age or HIV status
were observed between cases and controls (data not
shown here). A significant difference in the distribution
of the smoking status was found between the cases and
the controls (P = 0.004) (data not shown here). Subse-
quently, all the analyses were adjusted for the smoking
status along with ethnicity. The observed genotype fre-
quencies for CCR2-V64I polymorphism in the controls
were not in Hardy-Weinberg equilibrium (P = 0.001)
(data not shown here). This could be due to the fact the
our controls were not a randomly chosen population
rather handpicked in a 3:1 matched ratio to the cases on
decade of age, ethnic group and area of residence (urban/
rural).
Clinical specimens
Blood was collected from cases and controls, following
written informed consent and stored at -80°C. The
genetic study was approved by the University of Cape
Town Human Ethics Committee (REC REF: 075/2009).
The subject identifiers were permanently unlinked from
the specimens.
Papanicolaou test
Endocervical scrapings were taken from the control
women to conduct papanicolaou test (Pap smear) to
check for their cytology status as previously described
[35]. For this paper samples positive for ASCUS (atypical
squamous cells of undetermined significance), LSIL or
HSIL were considered as abnormal cytology.
Among 1258 controls for which pap smear results were
available, 185 (15%) were positive. Of the 185 pap smear
positive samples, 91 (49%) were classified as SIL and the
remaining 94 (51%) were classified as ascus (Atypical
Squamous Cells of Undetermined Significance) positive.
Among those 91 SIL positive samples, 46 (51%) were pos-
itive for LSIL and 45 (49%) were positive for HSIL.
High-risk HPV type detection
Endocervical scrapings from control women were
assayed for HPV infection using the Digene Hybrid Cap-
ture II HPV Test for the detection of high risk HPV types
16/18/31/33/35/39/45/51/52/56/58/59/68 and were clas-
sified positive according to the manufacturer's instruc-
tions (Digene Corporation, Gaithersburg, MD, USA) [35].
Extraction of genomic DNA
The genomic DNA was extracted using TotalNucleicAcid
Extraction kit for MagNA Pure Compact nucleic acid
extractor (Roche Diagnostics, Germany).
Determination of CCR2-V64I polymorphism
The CCR2-V64I polymorphism was determined by poly-
merase chain reaction (PCR) using sequence-specific
primers (SSP) followed by agarose gel electrophoresis.
Two PCR reactions were carried out for each sample
using two different forward primers (CCR2-64V and
CCR2-64I) and a reverse primer. 130 ng of genomic DNA
was amplified in a 10-μl reaction mixture containing 10
picomoles of each CCR2-V64I primers: F(CCR2-64V),
5'TGGGCAACATGCTGGTCG3' or F(CCR2-64I),
5'TGGGCAACATGCTGGTCA3' and R,
5'TGGAAAATAAGGGCCACAGAC3' [37] and 5-μl 2 ×
ImmoMix™ (Bioline). PCR cycle reactions were per-
formed on an ABI 2720 Thermal Cycler (Applied Biosys-
tems, Foster City, CA) beginning with a denaturing step
at 95°C for 2.5 min followed by 10 higher-stringency
cycles of denaturing at 94°C for 25 s, annealing at 60°C for
45 s and extension at 72°C for 45 s again followed by 21
lower-stringency cycles of denaturing at 94°C for 25 s,
annealing at 58°C for 40 s and extension at 72°C for 40 s
with a final extension at 72°C for 6 min. The PCR reaction
conditions were adapted and modified from Tang J et. al.
[37].
The amplified PCR products of 413 base pairs (bp) were
analysed by running on 1.5% agarose gel stained withChatterjee et al. BMC Cancer 2010, 10:278
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ethidium bromide using an O'GeneRuler™ 50 bp DNA
Ladder , ready-to-use (Fermentas Inc, Ontario, Canada).
The samples with a wild type allele (G) at position 190 of
the CCR2 gene amplified the PCR containing CCR2-64V
forward primer and showed no products for the PCR
containing CCR2-64I forward primer. Likewise, samples
with a mutant allele (A) at position 190 of the CCR2 gene
did not show any product for the PCR containing CCR2-
64V forward primer rather amplified the PCR containing
CCR2-64I forward primer. The heterozygous samples
showed products for both the PCR containing CCR2-64V
as well as CCR2-64I forward primers (Figure 1).
The genotyping was cross-checked by DNA sequencing
of total 40 samples, 10 each for wild type, mutant type,
heterozygous and 10 randomly selected samples using a
forward primer (5'TACGGTGCTCCCTGTCATAAA3')
and the same reverse primer previously used for genotyp-
ing of CCR2. The DNA sequencing was done using a Big-
Dye Teminator V3.1 Cycle sequencing kit (Applied
Biosystems, Foster City, CA) following the manufacturers
protocol. Other than the mutant type samples, all the
other samples showed 100% confirmation of our geno-
type results. Due to some ambiguity in the first 10 ran-
domly selected mutant type samples, we decided to
sequence all the mutant samples. Among all the 125
mutant samples (as assigned according to PCR amplifica-
tion and agarose gel results) only 3 did not show any
result in both forward and reverse primer sequencing and
were excluded from the final analysis. Rest of the 122
samples showed clear sequencing results of GG, AG or
AA and were scored accordingly.
Statistical Analysis
The genotype distributions were tested for Hardy-Wein-
berg equilibrium in cases and controls. Logistic regres-
sion was used to test for genotype associations with
c e r v i x  c a n c e r  s t a t u s  a s  w e l l  a s  b a s e l i n e  c h a r a c t e r i s t i c s
(age, ethnicity and smoking status) and secondary out-
comes such as HIV status and abnormal cytology (Pap
smear) in the control group. Statistical analyses were
done using Stata 9 software.
Results
The role of CCR2-V64I polymorphism was investigated
in the risk of cancer of the cervix, pre-cancers and HPV
infection in South African women of black and mixed-
ancestry origin.
Genotyping data for CCR2-V64I  polymorphism was
obtained on 1378 of the 1432 control specimens. The fre-
quency of CCR2-64I variant was 39% in black cases and
20% in the black controls and 40% in mixed-ancestry
cases and 18% in mixed-ancestry controls. A statistically
significant, association was found with CCR2-64I variant
(P = 0.001) and cervical cancer cases and controls after
adjusting for ethnicity and smoking (Table 1).
Since cervical cancer is a multi-step process which
starts with HPV infection it was of interest to determine
at which stage the CCR2-64I variant became significant.
Therefore the CCR2-64I  variant was also studied in
women with cervical pre-cancers and HPV infection.
When the SIL positive (LSIL and HSIL positive) controls
(n = 91) were compared with the invasive cervical cancer
cases (n = 446) for CCR2-V64I polymorphism, a statisti-
cally significant association was found with the presence
of CCR2-64I variant (P = 0.001) in the invasive cancers
adjusted for ethnicity and smoking (Table 2). This result
indicated a difference in the CCR2-64I variant of women
who developed invasive cancer compared to the women
with pre-cancers.
Since the association was found with cancer it was then
determined if the same association could be observed in
pre-cancers within the control group. The association of
CCR2-V64I polymorphism with abnormal cytology sta-
tus, HSIL status and high risk HPV status was investi-
gated in the control group. Both abnormal cytology (P =
0.437) (Table 3) and high risk HPV status (P = 0.913)
(Table 4) were not found to be associated with CCR2-64I
variant in the control group adjusted for ethnicity and
smoking. Comparing only the HSIL positive samples with
all the normal cytology samples also did not show any sig-
nificant association (P = 0.157) in controls adjusted for
ethnicity and smoking (Table 5).
Discussion
Polymorphisms in the CCR2 gene that alters the mac-
rophage recruitment have been reported to influence a
number of diseases including AIDS [20-23], multiple
sclerosis [24], breast cancer [25], carotid atherosclerosis
[26] and renal transplant rejection [27]. This polymor-
phism has also been associated with cervical cancer in
two different populations [28-31].
Persistent HPV infection of epithelial cells is necessary
for the carcinogenesis of the uterine cervix, but not all
HPV infected cervical lesions progress to cervical cancer.
In addition many pre-cancers do not progress to invasive
cancer and can regress. Chemokines are regarded as an
Figure 1 Analysis of the CCR2-V64I genotypes on agarose gel. L = 
DNA ladder, samples 1 and 2 = GG (CCR2-64V - wild type homozy-
gous), samples 3 and 4 = GA (CCR2-V64I - heterozygous), samples 5 
and 6 = AA (CCR2-64I - mutant type homozygous), W = PCR amplifying 
wild type variant (CCR2-64V), M = PCR amplifying mutant type variant 
(CCR2-64I).Chatterjee et al. BMC Cancer 2010, 10:278
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important cofactor in the progression of the cervical
lesions to cancer of the cervix [7].
We are the first to study the frequency of the CCR2-
V64I  polymorphism in an indigenous black African as
well as in a mixed-ancestry population. We found a statis-
tically significant association of CCR2-64I variant (P =
0.001) with cervical cancer in African black and mixed-
ancestry women adjusted for ethnicity and smoking. Our
data suggests that women carrying A allele (P = 0.001, OR
(95% CI) = 6.14 (4.79-7.86)) and A/A genotype (P = 0.002,
OR (95% CI) = 3.99 (1.68-9.50)) at position 190 of the
CCR2 gene have increased risk of cervical cancer com-
pared to women carrying the G variant of it. When the
SIL controls were compared with cervical cancer cases, it
was found that CCR2-64I  carriers are at more risk of
developing cervical cancer (P = 0.001, OR (95% CI) = 6.86
(4.19-11.21)) from SIL. The analysis of CCR2-V64I geno-
types with abnormal cytology (P = 0.437), presence of
high risk HPV infection (P = 0.913) and HSIL positive
status (P = 0.157) did not show any statistically significant
association in the control group.
Our results showing susceptible effect of CCR2-64I
variant to cervical cancer (compared to controls without
cancer of the cervix and SIL positive controls) do not
agree with those of two other groups, Coelho et al. [29]
and Ivansson et al [30]. Also our data showing no associa-
tion of CCR2-64I variant with HSIL when compared to
individuals with normal cytology, do not confirm Coelho
et. al. [28] who reported an increased risk of CCR2-64I
variant with HSIL. The contradictory results might be
due to one or several factors, including the difference in
ethnic origin of the populations studied the difference in
sample size and the high percentage of the mutant allele
(CCR2-64I) in our population. The fact that we did not
find any association with abnormal cytology, HSIL and
high risk HPV infection in the control group but found a
susceptible effect with cervical cancer suggests that
CCR2-64I variant is not associated with susceptibility to
HPV infection and pre-cancerous lesions in our popula-
Table 1: Counts (n), frequencies (%) and association statistics for CCR2-V64I genotypes for cases and controls
Controls (n = 1378) Cases (n = 446)
Black 305 (n = 22) Mixed-ancestry 1073 
(n = 78)
Black 106 (n = 24) Mixed-ancestry 
340 (n = 76)
Genotype-cervical cancer association, 
adjusted for ethnicity and smoking
Genotypes n (%) n (%) n (%) n (%) P-value OR (95% CI)
CCR2 GTA
GG 189 (62) 704 (66) 24 (23) 78 (23) - 1
AG 112 (37) 356 (33) 81 (76) 255 (75) 0.001 6.22 (4.85-7.97)
AA 4 (1) 13 (1) 1 (1) 7 (2) 0.002 3.99 (1.68-9.50)
AG + AA 116 (38) 369 (34) 82 (77) 262 (77) 0.001 6.14 (4.79-7.86)
P-values and OR (95% confidence intervals) are for test of genotype or additive allelic association with cervix cancer risk, adjusted for ethnicity 
and smoking. P-values next to genotype names are for joint model, others are for ORs of specific genotype compared to reference genotype, 
indicated with OR = 1. Cases = Women with cancer of the cervix (ICC), Controls = Women without cancer of the cervix.
Table 2: Association statistics for CCR2-V64I genotypes for cases and SIL positive controls
SIL positive controls (n = 91) Cases (n = 446)
Black 31 (34) Mixed-ancestry 60 (66) Black 106 (24) Mixed-ancestry 
340 (76)
Genotype-cervical cancer 
association, adjusted for ethnicity 
and smoking
Genotypes n (%) n (%) n (%) n (%) P-value OR (95% CI)
CCR2 GTA
GG 21 (68) 40 (66) 24 (23) 78 (23) - 1
AG 9 (29) 19 (32) 81 (76) 255 (75) 0.001 7.18 (4.35-11.87)
AA 1 (3) 1 (2) 1 (1) 7 (2) 0.300 2.32 (0.47-11.36)
AG + AA 10 (32) 20 (33) 82 (77) 262 (77) 0.001 6.86 (4.19-11.21)
Cases = Women with cancer of the cervix (ICC), SIL positive controls = Women without cancer of the cervix (ICC) but positive for LSIL and HSIL by 
pap smear test.Chatterjee et al. BMC Cancer 2010, 10:278
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tion but increases the risk of ICC at a later stage during
the development of cancer of the cervix from HSIL (Fig-
ure 2). Our results showing no association of CCR2-64I
variant with HPV infection are in line with the findings of
Zheng B et. al [31].
HPV-infected epithelial cells do not elicit strong local
or systemic immune responses. MCP-1 plays an impor-
tant role in the development of tumours as it is one of the
major chemokines that induces recruitment of mac-
rophages in tumours including cervical cancer [14].
Recruitment and activation of macrophages is a vital pro-
cess for the inflammatory response of the human body.
Though macrophages display tumour cytotoxicity,
tumour-associated macrophages (TAMs) mainly have
protumour functions [38] and help in tumour angiogene-
sis. Increased expression of MCP-1 recruits more mac-
rophages which speed up the process of tumour
destruction or progression depending upon the type of
macrophages recruited. After the infection of epithelial
cells by HPV, the MCP-1 expression decreases from LSIL
to HSIL and increases again from HSIL to ICC [17].
T u m o u r  c e l l s  h a v e  b e e n  r e p o r t e d  w i t h  h i g h  l e v e l s  o f
MCP-1 expression [18]. Macrophages which are
recruited by MCP-1 chemokine, express CCR2 on their
cell surface. The CCR2-64I  variant is associated with
increased expression of CCR2A (due to increased stabil-
i t y  o f  C C R 2 A )  o n  t h e  c e l l  s u r f a c e  o f  m o n o cyt e s.  T h i s
increases the attraction of monocytes to tumour cells
p r o d u c i n g  M C P - 1 .  I n  e a r l y  s t a g e s  o f  i n f e c t i o n ,  t h e
increased recruitment of monocytes results in more mac-
rophages and associated cells (DC and NK cells) converg-
ing on the developing tumours to destroy the progressing
tumours cells. Therefore, increased expression of CCR2
receptors results in increased recruitment of mac-
rophages and possibly faster destruction of a developing
tumour. Thus the CCR2-64I variant might be associated
with reduced risk of developing cancer in the early phase.
Our results with HPV infected individuals do point
toward a reduced risk of CCR2-64I with abnormal cytol-
ogy and HSIL positivity when compared to individuals
with normal cytology (according to the tendencies of the
ORs) though not statistically significant.
However, once the tumour cells evade the immune sys-
tem, the macrophages that are recruited towards elimina-
Table 3: Association statistics for CCR2-V64I genotypes according to cytology in the control group
Normal cytology (n = 1070) Abnormal cytology (n = 185)
Black 210 (20) Mixed-ancestry 
860 (80)
Black 64 (35) Mixed-ancestry 
121 (65)
Genotype-abnormal cytology 
association, adjusted for ethnicity and 
smoking
Genotypes n (%) n (%) n (%) n (%) P-value OR (95% CI)
CCR2 GTA
GG 124 (59) 563 (66) 45 (70) 78 (64) - 1
AG 84 (40) 287 (33) 17 (27) 40 (33) 0.290 0.83 (0.59-1.17)
AA 2 (1) 10 (1) 2 (3) 3 (3) 0.134 2.28 (0.78-6.69)
AG + AA 86 (41) 297 (35) 19 (30) 43 (36) 0.437 0.88 (0.63-1.22)
Abnormal cytology = Positive for pap smear test (i.e. positive for ASCUS + positive for LSIL + positive for HSIL), Normal cytology = Negative for 
pap smear test.
Table 4: Association statistics for CCR2-V64I genotype for high risk HPV infection in the control group
High risk HPV positive (201) High risk HPV negative (1053)
Black 62 (31) Mixed-ancestry 
139 (69)
Black 212 (20) Mixed-ancestry 841 
(80)
Genotype-high risk HPV association, 
adjusted for ethnicity and smoking
Genotypes n (%) n (%) n (%) n (%) P-value OR (95% CI)
CCR2 GTA
GG 34 (55) 94 (68) 135 (64) 546 (65) - 1
AG 27 (43) 41 (29) 74 (35) 286 (34) 0.904 0.98 (0.71-1.35)
AA 1 (2) 4 (3) 3 (1) 9 (1) 0.163 2.14 (0.73-6.25)
AG + AA 28 (45) 45 (32) 77 (36) 295 (35) 0.913 1.02 (0.74-1.40)
High risk HPV positive = Positive for Hybrid Capture II HPV Test, High risk HPV negative = Negative for Hybrid Capture II HPV Test.Chatterjee et al. BMC Cancer 2010, 10:278
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t i o n  o f  t h e  t u m o u r  s w i t c h  t o  T A M s  [ 1 5 , 1 6 ] .  T h e
increased stability of CCR2A due to CCR2-64I variant
sustains the tumours by continuously recruiting TAMs
that support tumour angiogenesis. It is not known when
this switch from tumour cytotoxic macrophages to TAMs
occurs during the development of cervical cancer. We
hypothesize that the switch occurs during early phase of
HSIL. Thus the CCR2-64I variant would be associated
with increased risk of cancer in the later stage of tumour
development (in this situation after progressing to HSIL)
when compared to the CCR2-64V variant which is associ-
ated with less stable CCR2A stability and expression.
Conclusions
Our study showed a significant association of CCR2-V64I
polymorphism with cervical cancer, but did not show any
association with HPV infection and pre-cancerous
lesions.  CCR2-64I  variant showed an increased risk of
cervical cancer but not with infection by HPV and pre-
cancerous lesions. This implies that this mutation is asso-
ciated with a late event in the progression to cervical can-
cer. Further studies are needed with patients in different
stages of cervical cancer to confirm our findings.
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